Research Grade Namilumab

Catalog No.

DHC06701

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

Granulocyte-macrophage colony-stimulating factor, Sargramostim, GMCSF, CSF, Colony-stimulating factor, CSF2, GM-CSF, Molgramostin

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P04141

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MT203, CAS: 1206681-39-1

Clone ID

Namilumab

Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial, PMID: 30999929

GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential, PMID: 25748625

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody, PMID: 30207587

Namilumab improves RA symptoms, PMID: 31048782

Pharmaco-Immunomodulatory Therapy in COVID-19, PMID: 32696108

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis, PMID: 28274253

Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men, PMID: 30168415

Targeting granulocyte-monocyte colony-stimulating factor in psoriasis. What a negative study can teach us, PMID: 31157451

Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects, PMID: 31486005

The European League Against Rheumatism (EULAR) - 16th Annual European Congress (June 10-13, 2015 - Rome, Italy), PMID: 26261853

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial., PMID:38942047

Compartment-specific protein interactions in beryllium lung disease., PMID:37965231

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial., PMID:34922649

Pharmaco-Immunomodulatory Therapy in COVID-19., PMID:32696108

Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects., PMID:31486005

Targeting granulocyte-monocyte colony-stimulating factor in psoriasis. What a negative study can teach us., PMID:31157451

Namilumab improves RA symptoms., PMID:31048782

Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial., PMID:30999929

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody., PMID:30207587

Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men
., PMID:30168415

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis., PMID:28274253

The European League Against Rheumatism (EULAR) - 16th Annual European Congress (June 10-13, 2015 - Rome, Italy)., PMID:26261853

GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential., PMID:25748625

Document Download

Research Grade Namilumab.pdf